Tag:
Venture Capital
Latest Headlines
Latest Headlines
Pharma VC embrace improves a biotech's chance of success
Over the last few years pharma's corporate venture arms have been stepping up their game, helping to fund more biotechs.
Venture capital circles turn dour in the face of some tough challenges
This year ended on a series of sour notes from venture groups that the biotech industry found impossible to ignore. The National Venture Capital Association helped get the party started with a survey
Seattle biotech upstart advances molecular "paint" for cancer cells
No matter how brilliant an academic drug program is, it won't become a commercial reality until a biopharma comes along, picks it up and proves it works in the clinic. Today Xconomy's Luke Timmerman
Amgen backs $30M venture round for IBS-focused Ardelyx
Amgen's venture arm has chipped in to a $30 million B round for Fremont, CA-based Ardelyx. The biotech plans to use a good deal of the cash to complete a Phase II study of a lead drug for
Spinifex closes Series B with $19M
Australia's Spinifex Pharmaceuticals says its added more than $6 million to its second round, bringing the Series B total to $19 million. GBS Venture Partners Limited, Brandon Capital Partners Pty
Sanger spinoff nabs $30M to develop better antibodies
Just a few months after stepping down as director of the prestigious Sanger Institute in the UK, Professor Allan Bradley has snared a $30 million venture round from The Wellcome Trust to finance a
VC/researcher team create biotech start-ups
The nexus between academic researchers and investors is a prime breeding ground for biotech start-ups. The Wall Street Journal profiles one prime example: MIT scientist Robert Langer and Polaris
AstraZeneca may shake up R&D with spin-off
AstraZeneca is considering spinning off its GI research institute into a separate company that would go out into the market and hunt for venture capital backing, according to Swedish newspaper
VC firm looks to early-stage research projects
Third Rock Ventures recently unveiled a $378 million life sciences fund which it says will concentrate on early-stage drug discovery--linking academic research to biotech companies. In an interview
